Medical Surveillance Program for NRC - Clinical Trial Material Facility - CTMF - Amendment 2
Medical Surveillance Program for NRC - Clinical Trial Material Facility - CTMF - Amendment 2 is a published development and funding opportunity on Contexium. The donor or funder is National Research Council of Canada (NRC). Project location(s): Canada. Applications close on 04 Sep 2026. Amendment 2- Change to Mandatory Criteria M9 (see document attached)
Opportunity overview
- Project name
- Medical Surveillance Program for NRC - Clinical Trial Material Facility - CTMF - Amendment 2
- Donor
- National Research Council of Canada (NRC)
Key details
- Opportunity start date
- Opportunity end date
- Project location(s)
- Canada
Summary
Frequently asked questions
What is Medical Surveillance Program for NRC - Clinical Trial Material Facility - CTMF - Amendment 2?
Medical Surveillance Program for NRC - Clinical Trial Material Facility - CTMF - Amendment 2 is a published development and funding opportunity on Contexium. The donor or funder is National Research Council of Canada (NRC). Project location(s): Canada. Applications close on 04 Sep 2026. Amendment 2- Change to Mandatory Criteria M9 (see document attached)
Who is funding Medical Surveillance Program for NRC - Clinical Trial Material Facility - CTMF - Amendment 2?
Medical Surveillance Program for NRC - Clinical Trial Material Facility - CTMF - Amendment 2 is funded by National Research Council of Canada (NRC).
When is the deadline to apply for Medical Surveillance Program for NRC - Clinical Trial Material Facility - CTMF - Amendment 2?
The application deadline is 04 Sep 2026 18:00 (UTC).
Where will the Medical Surveillance Program for NRC - Clinical Trial Material Facility - CTMF - Amendment 2 project take place?
The project location(s) are: Canada.
How can I apply for Medical Surveillance Program for NRC - Clinical Trial Material Facility - CTMF - Amendment 2?
Create a free Contexium account to view the full opportunity details and submit an application via the marketplace.